OS Therapies (OSTX) awards 500,000 stock options to CMO/CSO Petit

Rhea-AI Filing Summary

OS Therapies Inc. filed a report showing that senior officer Robert Petit, the company’s Chief Medical Officer and Chief Scientific Officer, received a new equity award. On October 21, 2025, he was granted stock options to purchase 500,000 shares of OS Therapies common stock at an exercise price of $1.80 per share.

The options are scheduled to vest in full on the one-year anniversary of the grant date, as long as he is still employed by OS Therapies at that time. After this transaction, Petit also holds 200,000 shares of OS Therapies common stock directly, in addition to the newly granted options.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

PETIT ROBERT

(Last) (First) (Middle)

C/O OS THERAPIES INCORPORATED

115 PULLMAN CROSSING ROAD, SUITE 103

(Street)

GRASONVILLE MD 21638

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
OS Therapies Inc [ OSTX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	See Remarks

3. Date of Earliest Transaction (Month/Day/Year)
10/21/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock								200,000	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock options (right to buy)	$1.8	10/21/2025		A		500,000		(1)	10/21/2035	Common Stock	500,000	$0	500,000	D

Explanation of Responses:

1. On October 21, 2025, the reporting person was granted options to purchase 500,000 shares of the issuer's common stock pursuant to the terms and conditions of a stock option award agreement. These options vest in full on the one-year anniversary of the date of grant, provided that the reporting person is serving as an employee of the issuer on such date.

Remarks:

Robert Petit is the Chief Medical Officer and Chief Scientific Officer of OS Therapies Incorporated.

	/s/ Robert Petit	12/19/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did OS Therapies (OSTX) report in this Form 4?

The filing reports that officer Robert Petit received stock options to purchase 500,000 shares of OS Therapies common stock on October 21, 2025.

What is the exercise price of the OS Therapies (OSTX) stock options granted to Robert Petit?

The stock options granted to Robert Petit have an exercise price of $1.80 per share for OS Therapies common stock.

When do the OS Therapies (OSTX) stock options granted to Robert Petit vest?

The options vest in full on the one-year anniversary of the October 21, 2025 grant date, provided he is still an employee of OS Therapies on that date.

How many OS Therapies (OSTX) shares does Robert Petit own after this transaction?

Following the reported transaction, Robert Petit beneficially owns 200,000 shares of OS Therapies common stock directly, plus 500,000 stock options.

What is Robert Petit’s role at OS Therapies (OSTX)?

Robert Petit serves as Chief Medical Officer and Chief Scientific Officer of OS Therapies Incorporated.

Is the Form 4 for OS Therapies (OSTX) filed by a single reporting person or a group?

The Form 4 is indicated as being filed by one reporting person, namely Robert Petit.